I maintain a 'Strong Buy' rating on McKesson with a fair value of $723 per share due to its robust oncology network and strong growth prospects. McKesson's minimal exposure to US-Mexico-Canada ...

Pharmaceutical drug wholesaler McKesson (NYSE:MCK) is the first dividend growth stock to consider as part of your passive income portfolio. This healthcare giant has a penchant for rewarding ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.